Sovremennye podkhody k diagnostike i lecheniyu yazvennogo kolita


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the modern classification of ulcerative colitis; latest guidelines for the diagnosis and treatment of various forms of the disease are considered. Treatment of ulcerative colitis includes dietary advice, administration of drug therapy (mesalazine, sulfasalazine, glucocorticosteroids, infliximab, azathioprine), psychosocial support, and surgery when appropriate. The choice of treatment is determined by the activity of inflammation, the volume of lesions of the colon, the presence of extra-intestinal manifestations, duration of history, efficacy and tolerability of previously received therapy, and the risk of complications of the disease.

References

  1. Гастроэнтерология. Национальное руководство / Под ред. В.Т. Ивашкина, Т.Л. Лапиной. М., 2008. 754 c.
  2. Marchal J., Hilsden R. Environment and epidemiology of inflammatory bowel disease. In Inflammatory bowel disease. Ed. Satsangi J., Sutherland L. Churchill-Livingstone, 2003. P. 17-28.
  3. Dignass A., et al. Second EUROPEAN evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J. Crohns Colitis. 2012; 6: 965-1030.
  4. Katsanos K.H., Vermeire S., Christodoulou D.K., et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion. 2007; 75: 113-21.
  5. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 2005; 19(Suppl. A): 5-36.
  6. Truelove S.C. et al. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. 1955; 2: 1041-48.
  7. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987; 317: 1625-9.
  8. Чашкова Е.Ю., Владимирова A.A., Неустроев В.Г. и др. Воспалительные заболевания толстой кишки -аспекты диагностики. Бюллетень Восточно-Сибирского научного центра СО РАМН. 2011; 4-2: 209-21.
  9. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm. Bowel. Dis. 2008; 14: 1432-42.
  10. Mindenmark M., Larsson A. Rulling out IBD estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin. Biochem. 2012; 45: 552-55.
  11. Корнеева О.И., Ивашкин В.Т. Антибиотикоассоциированный колит: патоморфология, клиника, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007; 17(3): 65-71.
  12. Ивашкин В.Т., Шептулин А.А., Шифрин О.С., Галимова С.Ф., Юрманова Е.Н. Микроскопический колит: клинические формы, диагностика, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006; 16(6): 56-60.
  13. Marshall J.K., Thabane M., Steinhart A.H., et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2010.
  14. van Bodegraven A.A., Boer R.O., Lourens J., Tuynman H.A., Sindram J.W. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment. Pharmacol. Ther. 1996; 10: 327-32.
  15. Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig. Dis. Sci. 2011; 56: 513-22.
  16. Marshall J.K., Irvine E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a metaanalysis. Gut. 1997; 40: 775-81.
  17. Gionchetti P., Rizzello F., Venturi A., et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis. Colon Rectum. 1998; 41: 93-7.
  18. Regueiro M., Loftus Jr. E.V., Steinhart A.H., Cohen R.D. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm. Bowel Dis. 2006; 12: 979-94.
  19. Ito H., Iida M., Matsumoto T., et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm. Bowel Dis. 2010; 16: 1567-74.
  20. Ford A.C., Achkar J.P., Khan K.J., et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am. J. Gastroenterol. 2011; 106: 601-16.
  21. Sutherland L., Macdonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2006: CD000543.
  22. Bebb J.R., Scott B.B. How effective are the usual treatments for ulcerative colitis? Aliment. Pharmacol. Ther. 2004; 20: 143-49.
  23. Kamm M.A., Sandborn W.J., Gassull M., et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132: 66-75.
  24. d'Albasio G., Pacini F., Camarri E., et al. Combined therapy wth 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative coltis: a randomized double-blind study. Am. J. Gastroenterol. 1997; 92: 1143-47.
  25. Travis S. What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis? Nat. Clin. Pract. Gastroenterol. Hepatol. 2005; 2: 564-65.
  26. Fockens P., Mulder C.J., Tytgat G.N., et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur. J. Gastroenterol. Hepatol. 1995; 7: 1025-30.
  27. Kane S.V., Cohen R.D., Aikens J.E., Hanauer S.B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am. J. Gastroenterol. 2001; 96: 2929-33.
  28. Kane S., Huo D., Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin. Gastroenterol. Hepatol. 2003; 1: 170- 73.
  29. Kamm M.A., Lichtenstein G.R., Sandborn W.J., et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008; 57(7): 893-902.
  30. Gisbert J.P., Linares P.M., McNicholl A.G., Mate J., Gomollon F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative coltis. Aliment. Pharmacol. Ther. 2009; 30: 126-37.
  31. Panaccione R., Ghosh S., Middleton S., et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J. Crohns Coltis. 2011; 5: 13.
  32. Reinisch W., Sandborn W.J., Rutgeerts P., et al. Longterm infliximab maintenance therapy for ulcerative coltis: the ACT-1 and -2 extension studies. Inflamm. Bowel. Dis. 2012; 18: 201-11.
  33. Gonzalez-Huix F., Fernandez-Banares F., Esteve-Comas M., et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative coltis. Am. J. Gastroenterol. 1993; 88: 227-32.
  34. Khan K.J., Ullman T.A., Ford A.C., et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 2011; 106: 661-73.
  35. Van Assche G., D'Haens G., Noman M., et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative coltis. Gastroenterology. 2003; 125: 1025-31.
  36. Sjoberg M., Walch A., Meshkat M., et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm. Bowel Dis. 2012; 18(2): 212-18.
  37. Sokol H., Seksik P., Carrat F., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010; 59: 1363-68.
  38. Lennard-Jones J.E., Ritchie J.K., Hilder W., Spicer C.C. Assessment of severity in coltis: a preliminary study. Gut. 1975; 16: 579-84.
  39. Travis S.P., Farrant J.M., Ricketts C., et al. Predicting outcome in severe ulcerative colitis. Gut. 1996; 38: 905-10.
  40. Lindgren S.C., Flood L.M., Kilander A.F., et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 1998; 10: 831-35.
  41. Benazzato L., D'Inca R., Grigoletto F., et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig. Liver Dis. 2004; 36: 461-66.
  42. Almer S., Bodemar G., Franzen L., et al. Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet. 1996; 347: 1731-35.
  43. Carbonnel F., Lavergne A., Lemann M., et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig. Dis. Sci. 1994; 39: 1550-57.
  44. Ferrante M., Vermeire S., Katsanos K.H. Predictors of early response to infliximab in patients wth ulcerative coltis. Inflamm. Bowel Dis. 2007; 13(2): 123-28.
  45. Gonzalez-Lama Y., Fernandez-Blanco I., Lopez-SanRoman A. Open-label infliximab therapy in ulcerative coltis: a multicenter survey of results and predictors of response. Hepatogastroenterology. 2008; 55(86-87): 1609-14.
  46. Fasanmade A.A., Adedokun O.J., Olson A., Strauss R., Davis H.M. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative coltis. Int. J. Clin. Pharmacol. Ther. 2010; 48(5): 297-308.
  47. Oussalah A., Evesque L., Laharie D., Roblin X. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am. J. Gastroenterol. 2010; 105(12): 2617-25.
  48. Головенко А.О., Халиф И.Л., Головенко О.В., Веселов В.В. Предикторы эффективности инфликсимаба у больных с тяжелой атакой язвенного колита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013; 3.
  49. American Thoracic Society / Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am. J. Respir. Crit. Care. Med. 2005; 172(9): 1169-227.
  50. Rahier, J.F., Ben-Horin S., Chowers Y., et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns Colitis. 2009; 3(2): 47-91.
  51. Справочник по колопроктологии / Под редакцией Ю.А. Шелыгина, Л.А. Благодарного. Литтерра, 2012. C. 460-522.
  52. Berndtsson I., Oresland T. Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis - a prospective study. Colorectal. Dis. 2003; 5: 173 - 79.
  53. Marcello P.W., Roberts P.L., Schoetz Jr D.J., et al. Long-term results of the ileoanal pouch procedure. Arch Surg 1993; 128: 500-3 [discussion 503-4].
  54. Sagar P.M., Pemberton J.H. Ileo-anal pouch function and dysfunction. Dig. Dis. 1997; 15: 172-88.
  55. Simchuk E.J., Thirlby R.C. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J. Surg. 2000; 24: 851-56.
  56. Ferrante M., D'Hoore A., Vermeire S., et al. Corticosteroids but not infliximab increase shortterm postoperative infectious complications in patients wth ulcerative coltis. Inflamm. Bowel. Dis. 2009; 15: 1062-70.
  57. Lake J.P., Firoozmand E., Kang J.C., et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J. Gastrointest. Surg. 2004; 8: 547-51.
  58. Pugliese D., Armuzzi A., Rizzo G., et al. Effect of anti-TNF-alpha treatment on short-term post-operative complications in patients with inflammatory bowel disease. Gut. 2010; 59 (Suppl. III): A13.
  59. Subramanian V., Pollok R.C., Kang J.Y., Kumar D. Systematic review of postoperative complications in patients wth in flammatory bowel disease treated with immunomodulators. Br. J. Surg. 2006; 93: 793-99.
  60. Mahadevan U., Loftus Jr E.V., Tremaine W.J., et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative coltis is not associated with increased postoperative complications. Inflamm. Bowel Dis. 2002; 8: 311-16.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies